• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NanoViricides denies $4.5B acquisition rumor

NanoViricides denies $4.5B acquisition rumor

March 10, 2014
CenterWatch Staff

NanoViricides, a development stage company creating special purpose nanomaterials for viral therapy, has denied a statement made in a blog post on the Seeking Alpha web site that it is being acquired for $2.25 billion to $4.5 billion.

The article was filed by Mathew Rohlad in his instablog on the Seeking Alpha web site. He identified himself as an investor in “undervalued large growth potential stocks."

The article NanoViricides (NNVC) Acquisition In Review claims an anonymous source informed the author an unidentified entity is “intent on acquiring NanoViricides” and this phantom entity valued the company “between 2.5 to 4.5 billion dollars."

The author did not contact any of the company’s executives prior to the posting, nor has Seeking Alpha attempted to verify any portion of the story with the company.

NanoViricides said it has no knowledge of being an acquisition target and has not had any discussions of such nature with any parties. Eugene Seymour, M.D., MPH, co-founder and CEO of NanoViricides, said, “We find it odd that Seeking Alpha would publish one story claiming the company has no value and a second claiming that it is about to be acquired for possibly up to $4.5 billion.”

NanoViricides said it provides information regarding its achievements, major corporate events and business strategy via press releases, quarterly and annual reports and other SEC filings. It advised investors and shareholders to obtain their information from these authentic sources and perform due diligence based on credible and authoritative sources. The company further advised shareholders and investors they should not rely on false and baseless statements from unknown and phantom entities, such as this post and a prior post by an admitted short seller, both published on the Seeking Alpha web site.

The company has filed an action in the Supreme Court of the State of New York to compel Seeking Alpha to disclose the identity of the person who wrote and published the defamatory, malicious and libelous Feb. 11 article about the company on the Seeking Alpha web site.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing